Loveland Reporter Herald
In the Loveland Reporter Herald, Wyatt C. emphasizes that tying U.S. drug pricing to foreign government price controls through a Most Favored Nation model threatens to stifle pharmaceutical research and push critical development overseas to competitors like China, without any guarantee of lowering patient costs. Instead, Wyatt advocates for Congress to focus on domestic reforms, specifically restructuring the 340B drug pricing program to ensure large hospital systems pass massive discounts directly to patients in need rather than absorbing them into unaccountable operating budgets.